Peter Ferdinandy
Overview
Explore the profile of Peter Ferdinandy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
314
Citations
8135
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Szabados T, Makkos A, Agg B, Benczik B, Brenner G, Szabo M, et al.
Br J Pharmacol
. 2024 Oct;
182(2):432-450.
PMID: 39472767
Background And Purpose: MicroRNA (miRNA) therapy is a promising approach to induce cardioprotection. We have previously identified cardiac microRNA-125b* (microRNA-125b-2-3p; miR-125b*) as a potential cardioprotective miRNA, termed ProtectomiR. We aimed...
12.
Kleinbongard P, Arriola C, Badimon L, Crisostomo V, Giricz Z, Gyongyosi M, et al.
Basic Res Cardiol
. 2024 Oct;
119(6):893-909.
PMID: 39422732
Numerous cardioprotective interventions have been reported to reduce myocardial infarct size (IS) in pre-clinical studies. However, their translation for the benefit of patients with acute myocardial infarction (AMI) has been...
13.
Kestecher B, Nemeth K, Ghosal S, Sayour N, Gergely T, Bodnar B, et al.
Cardiovasc Diabetol
. 2024 Oct;
23(1):368.
PMID: 39420340
Aims: The association and co-isolation of low-density lipoproteins (LDL) and extracellular vesicles (EVs) have been shown in blood plasma. Here we explore this relationship to better understand the role of...
14.
Karaduzovic-Hadziabdic K, Adilovic M, Zhang L, Lumley A, Shah P, Shoaib M, et al.
Clin Transl Med
. 2024 Oct;
14(10):e70042.
PMID: 39370709
No abstract available.
15.
Nagy R, Makkos A, Baranyai T, Giricz Z, Szabo M, Kravcsenko-Kiss B, et al.
Br J Pharmacol
. 2024 Sep;
182(2):396-416.
PMID: 39294819
Background And Purpose: Cardioprotective miRNAs (protectomiRs) are promising therapeutic tools. Here, we aimed to identify protectomiRs in a translational porcine model of acute myocardial infarction (AMI) and to validate their...
16.
Bereczki Z, Benczik B, Balogh O, Marton S, Puhl E, Petervari M, et al.
Br J Pharmacol
. 2024 Sep;
182(2):340-379.
PMID: 39293936
Three types of highly promising small RNA therapeutics, namely, small interfering RNAs (siRNAs), microRNAs (miRNAs) and the RNA subtype of antisense oligonucleotides (ASOs), offer advantages over small-molecule drugs. These small...
17.
Sayour N, Gergely T, Varadi B, Toth V, Agg B, Kovacs T, et al.
ESC Heart Fail
. 2024 Sep;
12(1):87-100.
PMID: 39243187
Aims: Heart failure with reduced ejection fraction (HFrEF) is a leading cause of death worldwide; thus, therapeutic improvements are needed. In vivo preclinical models are essential to identify molecular drug...
18.
Gigante B, Tamargo J, Agewall S, Atar D, Berg J, Campo G, et al.
Eur Heart J Cardiovasc Pharmacother
. 2024 Sep;
10(7):614-645.
PMID: 39237457
Obesity and underweight are a growing health problem worldwide and a challenge for clinicians concerning antithrombotic therapy, due to the associated risks of thrombosis and/or bleeding. This clinical consensus statement...
19.
Schreckenberg R, Schulz R, Itani N, Ferdinandy P, Bencsik P, Szabados T, et al.
Redox Biol
. 2024 Aug;
76:103308.
PMID: 39167912
In rats decreased bioavailability of nitric oxide induces oxidative stress and right heart failure. Oxidative stress can activate matrix metalloproteinase-2 (MMP2). We addressed the question whether increasing oxidative defense by...
20.
Wang X, Izzo A, Papapetropoulos A, Alexander S, Cortese-Krott M, Kendall D, et al.
Br J Pharmacol
. 2024 Aug;
181(19):3547-3555.
PMID: 39128855
Natural products (NPs) have long been used as a rich source of bioactive compounds for drug development. Recent technological advancements have revitalised natural products research as evidenced by increased publications...